Quest Diagnostics Incorporated
DGX
Κατάταξη σε μετοχές
#929
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Τιμή μετοχής
$236.69
Κεφαλαιοποίηση
$26.12B
Αλλαγή (1 ημέρα)
0.80%
Αλλαγή (1 έτος)
24.31%
Χώρα
US
Εμπόριο Quest Diagnostics Incorporated (DGX)
Κατηγορία
Healthcare
Κέρδη για την Quest Diagnostics Incorporated (DGX)
Κέρδη τον Jun 2026 TTM: $1.42B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Quest Diagnostics Incorporated, τα τρέχοντα κέρδη της εταιρείας είναι $1.42B. Το 2024, η εταιρεία παρουσίασε κέρδη $1.19B, αύξηση σε σχέση με των κερδών του 2023 που ήταν $1.16B. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Quest Diagnostics Incorporated από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $1.42B | 4.34% |
| 2025 | $1.36B | 13.90% |
| 2024 | $1.19B | 3.29% |
| 2023 | $1.16B | -9.62% |
| 2022 | $1.28B | -52.22% |
| 2021 | $2.68B | 36.65% |
| 2020 | $1.96B | 72.90% |
| 2019 | $1.13B | 22.35% |
| 2018 | $926.00M | -10.10% |
| 2017 | $1.03B | -5.16% |
| 2016 | $1.09B | -1.54% |
| 2015 | $1.10B | 29.92% |
| 2014 | $849.00M | -37.02% |
| 2013 | $1.35B | 26.17% |
| 2012 | $1.07B | 24.77% |
| 2011 | $856.30M | -27.70% |
| 2010 | $1.18B | -3.55% |
| 2009 | $1.23B | 20.50% |
| 2008 | $1.02B | 11.68% |
| 2007 | $912.40M | -11.70% |
| 2006 | $1.03B | 13.49% |
| 2005 | $910.45M | 9.02% |
| 2004 | $835.13M | 13.19% |
| 2003 | $737.80M | 36.03% |
| 2002 | $542.38M | 63.07% |
| 2001 | $332.60M | 65.49% |
| 2000 | $200.98M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $7.61B | 436.22% |
US
|
|
| $4.76B | 235.59% |
US
|
|
| $-252.70M | -117.81% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 16.84% |
US
|
